170 related articles for article (PubMed ID: 9833604)
1. Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population.
Hoskins JM; Shenfield GM; Gross AS
Br J Clin Pharmacol; 1998 Nov; 46(5):499-504. PubMed ID: 9833604
[TBL] [Abstract][Full Text] [Related]
2. Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype.
Herrlin K; Massele AY; Rimoy G; Alm C; Rais M; Ericsson O; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 2000 Aug; 68(2):189-98. PubMed ID: 10976550
[TBL] [Abstract][Full Text] [Related]
3. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population.
Bathum L; Skjelbo E; Mutabingwa TK; Madsen H; Hørder M; Brøsen K
Br J Clin Pharmacol; 1999 Sep; 48(3):395-401. PubMed ID: 10510152
[TBL] [Abstract][Full Text] [Related]
4. Concordance between proguanil phenotype and CYP2C19 genotype in Chinese.
Hoskins JM; Shenfield GM; Gross AS
Eur J Clin Pharmacol; 2003 Nov; 59(8-9):611-4. PubMed ID: 13680037
[TBL] [Abstract][Full Text] [Related]
5. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations.
Kaneko A; Bergqvist Y; Taleo G; Kobayakawa T; Ishizaki T; Björkman A
Pharmacogenetics; 1999 Jun; 9(3):317-26. PubMed ID: 10471063
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
[TBL] [Abstract][Full Text] [Related]
7. Association between CYP2C19 genotype and proguanil oxidative polymorphism.
Coller JK; Somogyi AA; Bochner F
Br J Clin Pharmacol; 1997 Jun; 43(6):659-60. PubMed ID: 9205829
[TBL] [Abstract][Full Text] [Related]
8. Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil.
Kaneko A; Bergqvist Y; Takechi M; Kalkoa M; Kaneko O; Kobayakawa T; Ishizaki T; Björkman A
J Infect Dis; 1999 Apr; 179(4):974-9. PubMed ID: 10068594
[TBL] [Abstract][Full Text] [Related]
9. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments.
Funck-Brentano C; Becquemont L; Lenevu A; Roux A; Jaillon P; Beaune P
J Pharmacol Exp Ther; 1997 Feb; 280(2):730-8. PubMed ID: 9023285
[TBL] [Abstract][Full Text] [Related]
10. Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.
Coller JK; Somogyi AA; Bochner F
Br J Clin Pharmacol; 1999 Aug; 48(2):158-67. PubMed ID: 10417492
[TBL] [Abstract][Full Text] [Related]
11. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
[TBL] [Abstract][Full Text] [Related]
12. Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers.
Tushar T; Vinod T; Rajan S; Shashindran C; Adithan C
Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):269-72. PubMed ID: 17371531
[TBL] [Abstract][Full Text] [Related]
13. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
[TBL] [Abstract][Full Text] [Related]
14. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences.
Tamminga WJ; Wemer J; Oosterhuis B; Weiling J; Wilffert B; de Leij LF; de Zeeuw RA; Jonkman JH
Eur J Clin Pharmacol; 1999 May; 55(3):177-84. PubMed ID: 10379632
[TBL] [Abstract][Full Text] [Related]
15. Hepatic cytochrome P450 CYP2C activity in psoriasis: studies using proguanil as a probe compound.
Helsby NA; Ward SA; Parslew RA; Friedmann PS; Rhodes LE
Acta Derm Venereol; 1998 Mar; 78(2):81-3. PubMed ID: 9534880
[TBL] [Abstract][Full Text] [Related]
16. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
Brøsen K; de Morais SM; Meyer UA; Goldstein JA
Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772
[TBL] [Abstract][Full Text] [Related]
17. In vitro proguanil activation to cycloguanil is mediated by CYP2C19 and CYP3A4 in adult Chinese liver microsomes.
Lu AH; Shu Y; Huang SL; Wang W; Ou-Yang DS; Zhou HH
Acta Pharmacol Sin; 2000 Aug; 21(8):747-52. PubMed ID: 11501186
[TBL] [Abstract][Full Text] [Related]
18. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
[TBL] [Abstract][Full Text] [Related]
19. Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.
Rasmussen BB; Nielsen TL; Brøsen K
Eur J Clin Pharmacol; 1998; 54(9-10):735-40. PubMed ID: 9923577
[TBL] [Abstract][Full Text] [Related]
20. Polymorphic oxidative metabolism of proguanil in a Nigerian population.
Bolaji OO; Sadare IO; Babalola CP; Ogunbona FA
Eur J Clin Pharmacol; 2002 Nov; 58(8):543-5. PubMed ID: 12451432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
